Notizia - Recent Pharma, Healthcare and Biotech Happenings

Progenics got FDA Approval on Iobenguane I 131 for Rare Adrenal Gland Tumors  A good news for unresectable rare adrenal tumor  patients as oncologists now have a new treatment to offer . On July 30, 2018, the Food and Drug Administration approved Progenics Pharmaceuticals iobenguane I for adult and pediatric patients with iobenguane scan-positive, unresectable, locally advanced or metastatic pheochromocytoma (PPGL) who require systemic anticancer therapy. Pheochromocytomas are rare tumors of the adrenal glands. The FDA approval of iobenguane I 131 was based on data from a pivotal phase II, open-label, multicenter trial that was conducted under a SPA with the FDA.  Iobe...